The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

For Immediate Release

Chicago, IL - June 11, 2018 - announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol Myers BMY , Merck MRK , Roche RHHBY , Lilly LLY and AbbVie ABBV .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday's Analyst Blog:

Pharma Stock Roundup: Merck, Lilly & More

This week was ruled by cancer data presentations at the annual meeting of the American Society of Clinical Oncology ("ASCO") in Chicago by pharma bigwigs like Bristol Myers, Merck and Roche, among others. JAK inhibitors were in the news this week with Lilly finally gaining FDA approval for its rheumatoid arthritis ("RA") candidate Olumiant (baricitinib) in the United States while AbbVie presented positive top-line data from its fifth late-stage study on upadacitinib in RA.

Recap of the Week's Most Important Stories

Update from ASCO: Merck stole the show at ASCO after presenting data from several cancer studies of its PD-L1 inhibitor, Keytruda. Key presentations were from two pivotal lung cancer trials. KEYNOTE-042 study evaluated Keytruda monotherapy in newly-diagnosed lung cancer patients while KEYNOTE-407 study evaluated Keytruda in combination with chemotherapy in difficult-to treat squamous non-small cell lung cancer (NSCLC). Both the studies showed that treatment with Keytruda led to improved survival. Particularly, data from the KEYNOTE- 407 study, which evaluated Keytruda in combination with chemotherapy for the first-line treatment of metastatic squamous NSCLC was considered "practice changing" by investors.

Four and five years follow-up data presented from two advanced melanoma studies showed that treatment with Keytruda led to long-term survival benefit. Interim data from a cohort of a phase II study, KEYNOTE-158, evaluating Keytruda as a monotherapy in patients with previously treated advanced small cell lung cancer (SCLC) demonstrated encouraging response rates in the overall population of SCLC patients as well as in patients whose tumors express PD-L1. Keytruda also demonstrated encouraging ORR in studies evaluating the Lenvima/Keytruda combination in four different tumor types and Keytruda monotherapy for the first-line treatment of advanced clear cell RCC.

Bristol-Myers and Nektar Therapeutics (NKTR) presented preliminary data from a mid-stage study evaluating NKTR-214 in combination with Bristol-Myers'PD-L1 inhibitor, Opdivo in several tumor types. The response rates in melanoma and kidney cancer patients did not impress investors, resulting in a 42% drop in Nektar's stock on Monday. (Read more: Nektar and Bristol-Myers Present Data on Cancer Study )

Bristol-Myers also presented data on Opdivo at ASCO. In a late-stage study evaluating Opdivo versus Yervoy in a broad range of patients with resected stage III or IV melanoma, Opdivo demonstrated sustained, superior recurrence-free survival versus Yervoy. In another study, Opdivo plus chemotherapy showed improved PFS versus chemotherapy in first-line lung cancer patients with PD-L1 expression

Novartis (NVS) announced positive data from a combination study on breast cancer drug Kisqali and from two long-term leukemia studies on Tasigna. (Read more: Novartis Announces Positive Data on Kisqali and Tasigna ).

Roche presented data from a late-stage study, which showed that Tecentriq (atezolizumab) plus chemotherapy reduced the risk of disease worsening or death (PFS) by 29% in advanced squamous NSCLC patients versus chemotherapy alone.

AbbVie presented early data from a phase II study evaluating a combination of its cancer drugs Imbruvica plus Venclexta (venetoclax) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL). The data demonstrated high rates of responses in such patients. Also, interim data from a late-stage study evaluating Imbruvica plus Roche's Rituxan in Waldenström's macroglobulinemia, a rare form of Non-Hodgkin's lymphoma, showed that the combination significantly reduced the risk of disease progression or death by 80% compared to placebo plus Rituxan.

Lilly Gets FDA Nod for Lower Dose of Olumiant: Eli Lilly and partner Incyte gained FDA approval for the lower dose of (2 mg) of the companies' JAK inhibitor, Olumiant. The FDA did not approve the higher dose (4 mg) and the drug's label was approved with a boxed warning stating risk of serious infections, malignancies and thrombosis. Olumiant is already marketed in Europe and Japan and generated sales of $32.2 million in the first quarter of 2018. In the United States, Lilly faced significant trouble in getting FDA nod for Olumiant. In April last year, the FDA had issued a complete response letter for the new drug application seeking approval of Olumiant, requesting additional information to determine the most appropriate doses. This year in April, an FDA advisory committee had recommended approval of the lower dose of the drug while not recommending the higher dose of 4 mg on inadequate safety profile to support an approval relative to its benefits. (Read more: Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis ).

AbbVie's 5th Late-Stage Upadacitinib Study Succeeds: AbbVie's oral JAK-1 selective inhibitor, upadacitinib, met all primary as well as secondary endpoints in the fifth phase III study from its SELECT program. Top-line data from the study showed thata significantly higher proportion of patients treated with upadacitinib in both 15 and 30 mg doses achieved superior responses compared to chemotherapy agent methotrexate. AbbVie plans to submit regulatory applications for upadacitinib in rheumatoid arthritis in the second half of the year. (Read more: Abbvie's Upadacitinib Fifth RA Study Data Positive )

Glaxo Completes Buyout of Novartis' Stake in Consumer Healthcare JV : Glaxo announced that it has completed its previously announced deal to buy out Novartis' 36.5% stake in the Consumer HealthCare joint venture for $13 billion (£9.2 billion),

With the acquisition of Novartis' stake, Glaxo now has 100% ownership of its Consumer Healthcare unit, which includes products such as Sensodyne and Flonase. Glaxo and Novartis created the JV in 2015 as part of a three-part transaction between the two companies by combining their consumer divisions.

Roche's Haemophilia A Candidate Gets Priority Review : Roche's sBLA looking for label expansion of its drug, Hemlibra for people with haemophilia A without factor VIII inhibitors was granted priority review by the FDA. Hemlibra is presently marketed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia A patients with factor VIII inhibitors. With the FDA granting priority review, a decision is expected on Oct 14

Separately, Roche's cancer drug Rituxan gained FDA approval for a new indication, moderate to severe pemphigus vulgaris (PV), a potentially life-threatening disease

The NYSE ARCA Pharmaceutical Index rose 1.7% in the last five trading sessions.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Roche Holding AG (RHHBY): Free Stock Analysis Report

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.